{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:20:13Z","timestamp":1771928413202,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs. Some patients still develop severe refractory SLE despite conventional treatments. Belimumab, a biologic targeting B lymphocyte stimulator (BLyS), shows therapeutic promise in SLE, but its effects on pediatric patients remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study used CyTOF to analyze immunophenotypic changes before and after belimumab treatment and investigate immune features in refractory SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results showed that belimumab treatment primarily reduced transitional and na\u00efve B cells, and also decreased age-associated B cells (ABCs), a subset implicated in autoimmunity or chronic inflammation. Plasma cells and plasmablasts persisted in refractory cases. CD38 expression on B cells was elevated in severe disease and correlated with disease activity, while CD73 expression increased during recovery and inversely correlated with activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings indicate that combining belimumab with conventional therapy induces significant immune modulation, particularly within B cells. Persistent plasma cells and plasmablasts may contribute to disease refractoriness. CD38 and the CD73-mediated adenosine pathway may provide insights for future research strategies in SLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1699104","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:31:19Z","timestamp":1770013879000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CyTOF analysis of immune characteristics in cSLE: belimumab treatment and refractory cases"],"prefix":"10.3389","volume":"17","author":[{"given":"Ying","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongbin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Immunology, Boston Children\u2019s Hospital","place":["Boston, MA, United States"]},{"name":"Department of Pediatrics, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Pui","family":"Lam","sequence":"additional","affiliation":[{"name":"Division of Immunology, Boston Children\u2019s Hospital","place":["Boston, MA, United States"]},{"name":"Department of Pediatrics, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaona","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiru","family":"Su","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuli","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shenzhen Children\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"108274","DOI":"10.1016\/j.clim.2019.108274","article-title":"Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options","volume":"209","author":"Smith","year":"2019","journal-title":"Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-021-00457-z","article-title":"An update on the management of childhood-onset systemic lupus erythematosus","volume":"23","author":"Trindade","year":"2021","journal-title":"Paediatr Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06833-z","article-title":"Safety and efficacy of biologics in childhood systemic lupus erythematosus: a critical systematic review","volume":"43","author":"Elshaer","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12016-020-08817-2","article-title":"Management of severe refractory systemic lupus erythematosus: real-world experience and literature review","volume":"60","author":"Yang","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01824-x","article-title":"Refractory systemic lupus erythematosus: identification and pharmacological management","volume":"83","author":"Roccatello","year":"2023","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead406","article-title":"Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study","volume":"63","author":"Wang","year":"2024","journal-title":"Rheumatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.290","article-title":"Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus","volume":"91","author":"Dennis","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"827254","DOI":"10.1155\/2013\/827254","article-title":"B lymphocytes: development, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus","volume":"2013","author":"Tobon","year":"2013","journal-title":"Autoimmune Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.06.041","article-title":"The BAFF\/APRIL system: life beyond B lymphocytes","volume":"42","author":"Ng","year":"2005","journal-title":"Mol Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2015.020","article-title":"Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm","volume":"10","author":"Zunder","year":"2015","journal-title":"Nat Protoc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.22271","article-title":"Normalization of mass cytometry data with bead standards","volume":"83","author":"Finck","year":"2013","journal-title":"Cytometry Part A: J Int Soc Anal Cytol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-018-0016-7","article-title":"Metal-isotope-tagged monoclonal antibodies for high-dimensional mass cytometry","volume":"13","author":"Han","year":"2018","journal-title":"Nat Protoc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221346","article-title":"Age-associated B cells are heterogeneous and dynamic drivers of autoimmunity in mice","volume":"220","author":"Nickerson","year":"2023","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940416","article-title":"Belimumab in childhood systemic lupus erythematosus: A review of available data","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2027516","article-title":"Belimumab as add-on therapy in lupus nephritis","volume":"383","author":"Ward","year":"2020","journal-title":"New Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.12.035","article-title":"B cell alterations during BAFF inhibition with belimumab in SLE","volume":"40","author":"Ramskold","year":"2019","journal-title":"EBioMedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00433","article-title":"Association between changes in BLyS levels and the composition of B and T cell compartments in patients with refractory systemic lupus erythematosus treated with belimumab","volume":"10","author":"Regola","year":"2019","journal-title":"Front Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01187","article-title":"The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.3390\/ijms22052424","article-title":"Dysregulated CD38 expression on peripheral blood immune cell subsets in SLE","volume":"22","author":"Burns","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040168","article-title":"Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice","volume":"199","author":"Hoyer","year":"2004","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202317","article-title":"Pathogenic long-lived plasma cells and their survival niches in autoimmunity, Malignancy, and allergy","volume":"189","author":"Winter","year":"2012","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017004481","article-title":"Long-lived plasma cells in human bone marrow can be either CD19+ or CD19\u2013","volume":"1","author":"Brynjolfsson","year":"2017","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/lupus-2023-001112","article-title":"Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease","volume":"11","author":"McDonnell","year":"2024","journal-title":"Lupus Sci Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"New Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e003604","DOI":"10.1136\/rmdopen-2023-003604","article-title":"Daratumumab for autoimmune diseases: a systematic review","volume":"9","author":"Holzer MT","year":"2023","journal-title":"RMD Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e29848","DOI":"10.1016\/j.heliyon.2024.e29848","article-title":"The roles of adenosine signaling in systemic lupus erythematosus","volume":"10","author":"Dong","year":"2024","journal-title":"Heliyon"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400336","article-title":"A novel mechanism of B cell\u2013mediated immune suppression through CD73 expression and adenosine production","volume":"193","author":"Kaku","year":"2014","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01322","article-title":"Ectonucleotidase-mediated suppression of lupus autoimmunity and vascular dysfunction","volume":"9","author":"Knight","year":"2018","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"112743","DOI":"10.1016\/j.intimp.2024.112743","article-title":"The reduced frequency of CD39(+)CD73(+) B cell subsets in SLE patients is correlated with disease activity","volume":"140","author":"Dong","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aan8664","article-title":"Precursors of human CD4(+) cytotoxic T lymphocytes identified by single-cell transcriptome analysis","volume":"3","author":"Patil","year":"2018","journal-title":"Sci Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.2100017","article-title":"Granzyme-producing CD4 T cells in cancer and autoimmune disease","volume":"5","author":"Park","year":"2021","journal-title":"ImmunoHorizons"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1699104\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:28:58Z","timestamp":1771925338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1699104\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2026.1699104"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1699104","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"article-number":"1699104"}}